In this study, we aimed to improve our understanding of the limited efficacy of immune checkpoint inhibitors in EGFR-driven NSCLC patients and the role of oncogenic EGFR signalling for the immunosuppressive composition of the TME. Here, EGFR is linked to non-small cell lung carcinoma.